Anti-malaria humoral responses in children exposed to Plasmodium falciparum and Schistosoma haematobium.
Antibody responses directed against the Plasmodium falciparum antigens, total extract, anti-merozoite surface protein-3 (MSP3b) and glutamate-rich protein (Glurp-R0) were studied in 42 children exposed to both Schistosoma haematobium and P. falciparum infections. The association between levels of the anti-malaria IgG subclasses and IgM with host age, sex, schistosome infection intensity and schistosome specific antibodies was studied before chemotherapeutic treatment of schistosome infections. This showed a significant negative association between schistosome infection intensity and levels of IgG1, IgG3, and IgG4 directed against malaria total extract antigen, and a positive association between levels of anti-schistosome soluble egg antigen IgG2, IgG3, and IgG4 and levels of the same subclasses directed against malaria total extract antigens. The effect of treating schistosome infections with praziquantel on malaria specific responses was also studied. This treatment resulted in increases in significant IgG4 levels against MSP3b and IgM against Glurp R0. Treatment also resulted in a significant decrease in IgG4 levels against Glurp R0. Host age, sex or pre-treatment infection intensity was not associated with the magnitude of change in the two IgG4 responses while males showed a significantly higher increase in levels of IgM. The results suggest cross reactivity between schistosome and malaria antigens in this population.
Mutapi
F
F
School of Biological Sciences, Ashworth Laboratories, King's Buildings, University of Edinburgh, Edinburgh, UK. f.mutapi@ed.ac.uk
Roussilhon
C
C
Mduluza
T
T
Druilhe
P
P
D000293:Adolescent; D000818:Animals; D000871:Anthelmintics / Q000627:therapeutic use; D000913:Antibodies, Protozoan / Q000276:immunology; D000918:Antibody Specificity; D000953:Antigens, Protozoan / Q000276:immunology*; D002648:Child; D003429:Cross Reactions; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood / Q000145:classification / Q000276:immunology*; D016778:Malaria, Falciparum / Q000150:complications / Q000188:drug therapy / Q000276:immunology*; D008297:Male; D010446:Peptide Fragments / Q000276:immunology*; D010963:Plasmodium falciparum / Q000276:immunology; D011223:Praziquantel / Q000627:therapeutic use; D015800:Protozoan Proteins / Q000276:immunology*; D012548:Schistosoma haematobium / Q000276:immunology; D012553:Schistosomiasis haematobia / Q000150:complications / Q000188:drug therapy / Q000276:immunology*
D000871:Anthelmintics; D000913:Antibodies, Protozoan; D000953:Antigens, Protozoan; D007074:Immunoglobulin G; C506685:MSP3 protein, Plasmodium falciparum (181-276); D010446:Peptide Fragments; D015800:Protozoan Proteins; C072492:glutamate-rich protein, Plasmodium; D011223:Praziquantel